Staff Members - Benha University
The Impact of Comorbidities on the Outcomes of Egyptian COVID-19 Patients: A Follow-Up Study
• 2022
Publication Information
Authors
Reda M. Albadawy ,1 Bismeen A. Jadoon ,2 Mysara M. Mogahed ,3
Mohamed E. Ibrahim ,3 Tarek S. Essawy ,4 Ahmed M. A. Amin ,1
Marwa S. Abd-Elraouf ,5 and Mona A. Elawady 5
Keywords
Not Available
Journal
Not Available
Publisher
Not Available
Volume
Not Available
Issue
Not Available
Pages
Not Available
publication.type
Local
Paper Link
Not Available
Supplementary Materials
Not Available
Abstract
Objectives. +is study evaluated the clinical manifestation of COVID-19 and adverse outcomes in patients with comorbidities
(outcome: death). Methods. A comparative follow-up investigation involving 148 confirmed cases of COVID-19 was performed
for a month (between April and May 2020) at Qaha Hospital to describe the clinical characteristics and outcomes resulting from
comorbidities. Participants were divided into two clusters based on the presence of comorbidities. Group I comprised cases with
comorbidities, and Group II included subjects without comorbidity. Survival distributions were outlined for the group with
comorbidities after the follow-up period. Results. Fever (74.3%), headache (78.4%), cough (78.4%), sore throat (78.4%), fatigue
(78.4%), and shortness of breath (86.5%) were the most prevalent symptoms observed in COVID-19 patients with comorbidities.
Such patients also suffered from acute respiratory distress syndrome (37.8%) and pneumonia three times more than patients
without comorbidities. +e survival distributions were statistically significant (chi-square � 26.06, p ≤ 0.001). Conclusion. Multiple
comorbidities in COVID-19 patients are linked to severe clinical symptoms, disease complications, and critical disease progression.
+e presence of one or more comorbidities worsened the survival rate of patients.
(outcome: death). Methods. A comparative follow-up investigation involving 148 confirmed cases of COVID-19 was performed
for a month (between April and May 2020) at Qaha Hospital to describe the clinical characteristics and outcomes resulting from
comorbidities. Participants were divided into two clusters based on the presence of comorbidities. Group I comprised cases with
comorbidities, and Group II included subjects without comorbidity. Survival distributions were outlined for the group with
comorbidities after the follow-up period. Results. Fever (74.3%), headache (78.4%), cough (78.4%), sore throat (78.4%), fatigue
(78.4%), and shortness of breath (86.5%) were the most prevalent symptoms observed in COVID-19 patients with comorbidities.
Such patients also suffered from acute respiratory distress syndrome (37.8%) and pneumonia three times more than patients
without comorbidities. +e survival distributions were statistically significant (chi-square � 26.06, p ≤ 0.001). Conclusion. Multiple
comorbidities in COVID-19 patients are linked to severe clinical symptoms, disease complications, and critical disease progression.
+e presence of one or more comorbidities worsened the survival rate of patients.